


JC10 Rec'd PCT/PTO 07 DEC 2001

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 5-93)		ATTORNEY'S DOCKET NUMBER ST99019 US PCT U.S. APPLICATION NO. (If known, see C.F.R. 1.5) 10/018273
<p align="center">TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</p>		
INTERNATIONAL APPLICATION NO. PCT/FR00/01594	INTERNATIONAL FILING DATE 8 June 2000	PRIORITY DATE CLAIMED France 99/07,449 (11.06.1999)
TITLE OF INVENTION RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE TRANSPORTER (NIS)		
APPLICANT(S) FOR DO/EO/US PERRICAUDET, Michel; SCHLUMBERGER, Martin; YEH, Patrice; BOLAND-AUGE, Anne		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), and Power of Attorney (unexecuted). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. Below concern other document(s) or information included:		
<ol style="list-style-type: none"> <input type="checkbox"/> An information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information 		
CERTIFICATION UNDER 37 CFR 1.10		
"Express Mail" Mailing Number EV 047246355 US I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated Above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231, Attn. EO/US William C. Coppola (Type or print name of person mailing paper)		Date of Deposit 12/7/01  (Signature of person mailing paper)

U.S. APPLICATION NO. (If Known, see C.F.R. 1.5)	INTERNATIONAL APPLICATION NO. PCT/FR00/01594	ATTORNEY'S DOCKET NUMBER ST99019 US PCT
--	---	--

10/018273

JCO5 Rec'd PCT/PTO 07 DEC 2001

17. ☒ The following fees are submitted:
- Basic National Fee (37 CFR 1.492(a)(1)-(5):
 Search Report has been prepared by the EPO or JPO.....\$ 860.00
- International preliminary examination fee paid to USPTO (37 CFR 1.482)
\$ 720.00
- No international preliminary examination fee paid to USPTO
 (37 CFR 1.482)
 but international search fee paid to USPTO (37 CFR 1.445(a)(2))..\$ 790.00
- Neither international preliminary examination fee (37 CFR 1.482) nor
 International search fee (37 CFR 1.445(a)(2)) paid USPTO.....\$1070.00
- International preliminary examination fee paid to USPTO (37 CFR 1.482) and
 all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 98.00

CALCULATIONS

PTO use only

ENTER APPROPRIATE BASIC FEE AMOUNT =

860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30
 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$
 0.00

Claims	Number Filed	Number Extra	Rate
Total Claims	36 - 20 =	16	X \$ 18.00
Independent Claims	5 - 3 =	2	X \$ 80.00
Multiple dependent claim(s) (if applicable)			+ \$270.00

\$ 288.00
 \$ 160.00
 \$ 0.00

TOTAL OF ABOVE CALCULATIONS =

\$ 1308.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement
 must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$

Processing fee of \$130.00 for furnishing the English translation later the [] 20 [] 30
 months from the earliest claimed priority date (37 CFR 1.492(f)).

+
 \$ 0.00

TOTAL NATIONAL FEE =

\$ 1308.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
 accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$
 0.00

TOTAL FEES ENCLOSED =

\$

Amount to be
 refunded \$

\$1308.00 charged \$

- a. ☐ A check in the amount of \$_____ to cover the above fee is enclosed.
- b. ☒ Please charge my Deposit Account No. 18-1982 in the amount of \$1308.00 to cover the above fees.
 A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
 Deposit Account No. 18-1982. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))
 must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Customer No. 005487

Signature

Name: William C. Coppola

Registration Number: 41,686

Date: December 7, 2001

10/018273

J005 Rec'd PCT/PTO 07 DEC 2001

PATENT
ST99019


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): PERRICAUDET, ET AL. EXAMINER : UNASSIGNED
SERIAL NO. : UNASSIGNED ART UNIT : UNASSIGNED
FILED : DECEMBER 7, 2001
FOR : RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC
IODINE TRANSPORTER (NIS)

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States
Postal Service via EXPRESS MAIL with EXPRESS MAIL Label No.
EV047246355US in an envelope addressed to the COMMISSIONER FOR
PATENTS, WASHINGTON, DC 20231 on December 7, 2001.

William C. Coppola, Reg. No. 41,686
(Name of Registered Representative)


(Signature and Date)

12/7/01

PRELIMINARY AMENDMENT

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Dear Sir:

Please amend the above-identified Application as follows.

IN THE SPECIFICATION:

Page 1: between the title and the first paragraph, please insert the following:

PRIORITY CLAIM

This application is a 35 U.S.C. § 371 filing of PCT Application number PCT/FR00/01594
filed on June 8, 2000, which claims the benefit of French Application number 99 07449 filed

June 11, 1999.

IN THE CLAIMS:

Please cancel Claims 6, 12 and 16 without prejudice.

Please amend Claims 1-5, 7-11, 13-15, and 17-18 as follows:

1. (Amended) A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising at least one DNA sequence encoding the specific iodine transporter (Na^+/I^- Symporter) NIS or a derivative thereof, wherein said DNA sequence is placed under the control of a transcriptional promoter allowing its expression in tumor cells.

2. (Amended) The defective recombinant adenovirus of Claim 1, wherein the DNA sequence is a cDNA sequence.

3. (Amended) The defective recombinant adenovirus of Claim 1, wherein the DNA sequence is a gDNA sequence.

4. (Amended) The defective recombinant adenovirus of Claim 1, wherein the DNA sequence encodes the specific murine iodine transporter (Na^+/I^- Symporter) NIS.

5. (Amended) The defective recombinant adenovirus of Claim 1, wherein the DNA sequence encodes the specific human iodine transporter (Na^+/I^- Symporter) NIS.

7. (Amended) The defective recombinant adenovirus of Claim 1, wherein the transcriptional promoter is a viral promoter.

8. (Amended) A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising a cDNA sequence encoding the human iodine transporter NIS under the control of the CMV promoter.

9. (Amended) A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising a DNA sequence encoding the iodine transporter NIS or a derivative thereof under the control of a promoter allowing predominant expression in tumor cells.

10. (Amended) The defective recombinant adenovirus of Claim 9, wherein the promoter is selected from the group consisting of the regulatory sequence of the elastase I gene, the regulatory sequence of the insulin gene, the regulatory sequence of the gene for immunoglobulins, the regulatory gene of the mouse mammary tumor virus, the regulatory sequence of the PSA gene, the regulatory sequence of the alpha-fetoprotein gene, the regulatory sequence of the alpha 1-antitrypsin gene, the regulatory sequence of the β -globin gene, the regulatory sequence of the gene for basic myelin, the regulatory sequence of the gene for the myosin light chain 2, and the regulatory sequence of the gene for the gonadotrophin-releasing hormone.

11. (Amended) The defective recombinant adenovirus of Claim 1, further comprising a deletion of all or part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

13. (Amended) The defective recombinant adenovirus of Claim 1, wherein said adenovirus is a human adenovirus type Ad 2 or Ad 5 or a canine adenovirus type CAV-2.

14. (Amended) The defective recombinant adenovirus of Claim 1, further comprising at least one gene encoding a polypeptide involved in a peroxidase system.

15. (Amended) A pharmaceutical composition comprising said defective recombinant adenovirus of Claim 1 and a physiologically acceptable vehicle.

17. (Amended) The pharmaceutical composition of Claim 15, in injectable form.

18. (Amended) The pharmaceutical composition of Claim 15, comprising between 10^4 and 10^{14} pfu/ml defective recombinant adenoviruses, inclusive.

Please add the following New Claims:

--19. The defective recombinant adenovirus of Claim 7, wherein the viral promoter is selected from the group consisting of E1A, MLP, CMV, RSV-LTR, MT-1, and SV40.

20. The defective recombinant adenovirus of Claim 14, wherein said gene encoding a polypeptide involved in a peroxidase system comprises the gene for glucose oxidase or the gene for thyroperoxidase.

21. The pharmaceutical composition of Claim 18, comprising between 10^6 to 10^{11} pfu/ml defective recombinant adenoviruses, inclusive.

22. The defective recombinant promoter of Claim 4, further comprising a deletion of all or part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

23. The defective recombinant promoter of Claim 4, further comprising a gene encoding a polypeptide involved in the peroxidase system.

24. The defective recombinant promoter of Claim 5, further comprising a deletion of all or part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

25. The defective recombinant virus of Claim 5, further comprising further comprising a gene encoding a polypeptide involved in the peroxidase system.

26. The defective recombinant adenovirus of Claim 8, further comprising a deletion

of all or part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

27. The defective recombinant adenovirus of Claim 8, further comprising at least one gene encoding a polypeptide involved in a peroxidase system.

28. The defective recombinant adenovirus of Claim 9, further comprising a deletion of all or part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

29. The defective recombinant adenovirus of Claim 9, further comprising at least one gene encoding a polypeptide involved in a peroxidase system.

30. A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising a DNA sequence that encodes a specific murine iodine transporter (Na^+/I^- Symporter) NIS or a specific human iodine murine iodine transporter (Na^+/I^- Symporter) NIS, wherein said DNA sequence is placed under the control of a transcription promoter allowing its expression in tumor cells.

31. The defective recombinant adenovirus of Claim 30, wherein said defective recombinant adenovirus comprises a deletion of all or a part of an E1 region, a deletion of all or part of an E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the

E4 region.

32. The defective recombinant adenovirus of Claim 31, wherein said defective recombinant adenovirus comprises a gene that encodes a polypeptide involved in the peroxidase system.

33. A method for treating cancer in a subject comprising the steps of:

- (a) administering to the subject the recombinant defective adenovirus of Claim 1; and
- (b) administering to the subject a radioactive isotope of iodine

34. The method of Claim 33, further comprising the step of administering an anti-cancer agent to the subject.

35. The method of Claim 34, wherein the anti-cancer agent comprises a taxoid, a derivative of platinum, cis-platin, etoposide, etoposide phosphate, bleomycin, mitomycin C, CCNU, doxorubicin, daunorubicin, idarubicin, or ifosfamide.

36. A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising:

- (a) a DNA sequence that:
 - (i) encodes for a specific murine iodine transporter (Na⁺/I⁻ Symporter) NIS that is under the control of a transcriptional promoter that allows

- expression of said DNA sequence in tumor cells; or
- (ii) encodes for a specific human iodine transporter (Na^+/I^- Symporter) NIS that is under the control of a transcriptional promoter that allows expression of said DNA sequence in tumor cells;
- (b) a deletion of all or part of an E1 region, a deletion of all or part of an E2 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E2 region; and
- (c) a gene encoding a polypeptide involved in a peroxidase system.

37. A method for treating cancer in a subject comprising administering to the subject the defective recombinant adenovirus of Claim 36, and a radioactive isotope of iodine.

38. The method of Claim 37, further comprising administering an anti-cancer agent to the subject.--

REMARKS

Claims 1-18 are presently pending in this case. In this preliminary amendment, Applicants have canceled Claims 6, 12 and 16, without prejudice, have amended Claims 1-5, 7-11, 13-15, and 17-18, and have added new Claims 19-38. Applicants have also amended the instant Specification to include a Priority Claim. Support for amended Claims 1-5, 7-11, 13-15, and 17-18, as well as new Claims 19-38, can be found generally throughout the instant Specification, particularly at pages 27-28 and Claims 1-18 as filed. Consequently, the instant Amendment introduces no new matter into the instant Application. Attached hereto is a marked-

up version of the changes made to the amended Claims by the instant Amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"


Fees

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

CONCLUSION

Applicants respectfully submit that the Claims as amended are believed to be in condition for allowance. Thus, early and favorable action on the claims is earnestly solicited.

Respectfully submitted,



William C. Coppola
Attorney for Applicant(s)
Registration No. 41,686

AVENTIS PHARMACEUTICALS PRODUCTS INC.
Route 202-206; Mail Stop: EMC-G1
P.O. Box 6800
Bridgewater, NJ 08807
December 7, 2001

one of claims 1 to 3, characterized in that] the DNA sequence encodes the specific murine iodine transporter (Na⁺/I⁻ Symporter) NIS.

5. (Amended) The defective recombinant adenovirus of Claim 1, wherein [as claimed in one of claims 1 to 3, characterized in that] the DNA sequence encodes the specific human iodine transporter (Na⁺/I⁻ Symporter) NIS.

7. (Amended) The defective recombinant adenovirus of Claim 1, wherein [as claimed in claim 6, characterized in that] the transcriptional promoter is a viral promoter [is chosen from viral promoters, preferably from the promoters E1A, MLP, CMV and RSV-LTR, MT-1, SV40].

8. (Amended) A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising a cDNA sequence encoding the human iodine transporter NIS under the control of the CMV promoter.

9. (Amended) A defective recombinant adenovirus that is incapable of autonomously replicating, said defective recombinant adenovirus comprising a DNA sequence encoding the iodine transporter NIS or a derivative thereof under the control of a promoter allowing predominant expression in tumor cells.

10. (Amended) The defective recombinant adenovirus of Claim 9, wherein [as claimed in claim 9, characterized in that] the promoter is selected from the group consisting of [chosen

11. (Amended) The defective recombinant adenovirus of Claim 1, further comprising [as claimed in one of claims 1 to 10, characterized in that it that it comprises at least] a deletion of all or part of an [the] E1 region, [and] a deletion of all or part of an [the] E4 region, or a deletion of all or part of the E1 region and a deletion of all or part of the E4 region.

13. (Amended) The defective recombinant adenovirus of Claim 1, wherein said adenovirus [as claimed in one of claims 1 to 12, characterized in that it] is a human adenovirus type Ad 2 or Ad 5 or a canine adenovirus type CAV-2.

14. (Amended) The defective recombinant adenovirus of Claim 1, further comprising [as claimed in one of claims 1 to 13, characterized in that it comprises, in addition,] at least one gene encoding a polypeptide involved in a peroxidase system [such as the gene for glucose oxidase or for thyroperoxidase].

15. (Amended) A pharmaceutical composition comprising said defective recombinant adenovirus of Claim 1 and a physiologically acceptable vehicle [The use of the adenovirus as claimed in one of claims 1 to 14, for the preparation of a pharmaceutical composition intended for treating and/or for inhibiting the growth of tumors].

17. (Amended) The pharmaceutical composition of Claim 15, [as claimed in claim 16, characterized in that it is] in injectable form.

18. (Amended) The pharmaceutical composition of Claim 15, comprising [as claimed in claim 16 or 17, characterized in that it comprises] between 10^4 and 10^{14} pfu/ml[, and preferably 10^6 to 10^{11} pfu/ml] defective recombinant adenoviruses, inclusive.

7/PRTS

10/018273
JCO5 RECEIVED PCT/PTO 07 DEC 2007
12/7/01 VIA EXPRESS MAIL
EVO47246355US
PCT/FR00/01594

WO 00/76450

RECOMBINANT ADENOVIRUSES ENCODING THE SPECIFIC IODINE
TRANSPORTER (NIS)

The present invention relates to the field of
5 gene therapy and the treatment of tumors. The invention
relates more particularly to the introduction of a gene
encoding the specific iodine transporter (Na^+/I^-
Symporter) NIS into tumor cells by means of an
adenoviral vector in order to promote the accumulation
10 of iodine in these cells. The invention also relates to
the replication-defective recombinant adenoviruses
comprising the *nis* gene and the use of these vectors in
a method for treating cancers combining the transfer of
the *nis* gene into tumor cells and metabolic
15 radiotherapy with iodine-131.

Iodine-131 has been used for more than fifty
years in the treatment of differentiated thyroid
cancers. Its therapeutic efficacy is linked to the
radiation dose delivered to the tumor tissue. For
20 example, in the case of metastases, a tumor response
after treatment with iodine-131 is observed when the
dose delivered to the tumor tissue is greater than 80
grays whereas the level of tumor response is low or
zero for doses of less than 35 grays [Maxon, NEJM,
25 309 : 937-941, 1983]. It is possible to generally
estimate that the total doses necessary to treat or to
reduce the volume of a tumor vary between 40 and 60

grays according to their radiosensitivity. This total dose may be delivered over several treatments with iodine-131, as is carried out during the treatment of fixed metastases of differentiated thyroid cancer.

5 The radiation dose delivered to the tumor tissue depends on two biological factors: the effective half-life (T_{eff}) of iodine-131 in the tumor tissue and the radioactive concentration.

 - The effective half-life (T_{eff}) of iodine-131
10 in the tumor tissue depends on the biological half-life (T_{biol}) and the physical half-life (T_{phys}) according to the relationship $1/T_{eff} = 1/T_{biol} + 1/T_{phys}$. The biological half-life (T_{biol}) of iodine-131 in the fixed cells depends on their capacity for organification of iodine.
15 In the absence of organification, as for example in nonthyroid cells, the biological half-life is short, of a few hours to a few tens of hours. The physical half-life (T_{phys}) of iodine-131 is 8.02 days. Thus, at best, it is possible to estimate that the effective half-life
20 of iodine-131 in a tumor tissue is a few hours to a few tens of hours.

 - The radioactive concentration is the ratio between the overall fixing of iodine-131 by the tumor tissue and the mass of this tissue.

25 By way of example, for an iodine fixing of 0.1% of the activity administered per 1 g of tissue and an effective half-life of 1.5 days, it is possible to estimate that the administration of 3.7 gigabecquerel

(or 100 mCi) delivers a dose of 30 grays to the tumor tissue.

The overall fixing of iodine-131 is a parameter which depends, on the one hand, on the activity of the iodine-131 administered to the patient and, on the other hand, on the capacities of the tumor tissue to concentrate the iodine-131.

- The maximum activity of iodine-131 which can be administered to a patient is limited by the iodine toxicity of iodine-131 resulting from the irradiation doses delivered to healthy tissues and in particular to the bone marrow. Thus, in the case of thyroid cancer, the therapeutic activities administered, while the patients are in a state of hypothyroidism, are generally between 3.7 and 10 GBq (100 to 300 mCi). The maximum activities which can be administered to euthyroid patients are higher because the retention of iodine is then twice as low as that observed in the case of hypothyroidism; they reach values of between 8.5 and 22.2 GBq (500 to 600 mCi).

- The capacity of normal tissue to concentrate iodine-131, for a given activity administered to the patient, depends on the level of expression of the iodine symporter and its biological activity. This was demonstrated by the study of normal and pathological human thyroid tissues and by *in vitro* studies of the NIS activity. The specific activity of iodine-131 being high, no saturation phenomenon with

increase in the activity of iodine-131 administered was observed.

Because of the limitation of the maximum activity of iodine-131 which can be administered to the patient, it would be desirable to be able to increase the capacity of the tumor tissue to concentrate iodine-131 in order to increase the overall fixing of iodine-131.

It is also critical that the increase in the fixing of iodine occurs homogeneously in the tumor tissue. Indeed, the fixing of iodine in a fixing tissue may be very heterogeneous from one cell to another, or even from one tumor region to another. The irradiation dose in the tumor tissue is essentially delivered by the β emission of iodine-131. However, its path in biological tissues is at most 2 to 3 mm. Furthermore, around a localized source, the irradiation dose decreases exponentially with distance. These elements reinforce the importance of reaching a high radioactive concentration in the fixing tumor regions and, on the other hand, the need to obtain a fixing of iodine which is as homogeneous as possible.

It should be noted that the fixing of iodine-131 by the human thyroid, and therefore its irradiation, can be easily suppressed (unmeasurable fixing of iodine-131) by the administration of L-triiodothyronine 1 $\mu\text{g/kg/day}$ divided into three daily doses for three weeks.

The NIS transporter is responsible for the concentration of circulating iodine (in the form of iodide I^-) by the thyreocytes [for a review see P. Thomopoulos, Médecine et Science, vol 4 (10), p. 825-828]. The concentration of iodine in these cells exhibits the following characteristics: the iodine is concentrated by a factor of 30 to 40 fold against an electrochemical gradient; it requires the presence of sodium (Na^+); this involves active transport; it is competitively inhibited by certain anions, such as thiocyanate, perchlorate, pertechnetate. The concentration of iodine by the thyreocytes is followed by the organification of the iodine and the synthesis of iodotyrosines and of thyroid hormones (thyroxine T4 and triiodothyronine T3).

The genes encoding the murine transporter [Dai et al. Nature 379 : 458-460 (1996)] and the human transporter [Smanik P.A. et al. Biochem. Biophys. Res. Commun. 226 : 339 - 345 (1996)] of NIS iodine have been isolated; they are 84% identical. The gene is located on chromosome 19p in the human species. It comprises 15 exons separated by 14 introns. Its transcription gives rise to two forms by alternative splicing, of which the long form predominates in the thyroid. The protein has a molecular weight of 55 kDa, reaching 80 kDa after glycosylation. It is located in the laterobasal membrane of the thyreocytes. Its amino-terminal and carboxy-terminal ends are intracellular

while the remainder of the peptide chain comprises 13 transmembrane segments joined by intracellular and extracellular loops [Levy et al., 1998. J. Biol. Chem. 273 : 22657-22663]. The introduction of the gene

5 encoding NIS into nonthyroid cells confers on them the capacity to capture iodine, with the same properties as the thyreocytes, in particular the necessary presence of sodium (Na^+) and the inhibition by perchlorate anions.

10 The transcription of the *nis* gene is activated in the thyreocytes by TSH. This effect is mediated by cyclic AMP. The half-life of the protein, in the murin thyreocytes is 4 days [Paire A. et al. J. Biol. Chem. 272 : 18245 - 18249 (1997)]. In the
15 extrathyroid tissues, the activity of the gene is lower than that of the thyroid in the basal state. This is presumably due to the stimulation of the transcription of the *nis* gene in the thyreocytes, by the specific transcription factor TTF-1 (thyroid transcription
20 factor 1), which can bind to the promoter of the thyroid *nis* gene, but not to that of other tissues [Endo T. et al. Mol. Endocrinol. 11 : 1747 - 1755 (1997)]. Apart from the thyroid, certain tissues are capable of capturing and of concentrating iodine, in
25 particular the salivary glands and the gastric mucous membrane.

A recent study reports the transfer of the *nis* gene by means of a retroviral vector into human or

murine tumor cells [Mandell et al. Cancer Research 59 :
661-668 (1999)]. These results are of interest in that
they show that it is possible to express the *nis* gene
in nonthyroid cells and to observe concentration of
5 iodine in cells which do not naturally accumulate this
element. However, a number of limiting factors remain
to be overcome in order to reach a sufficient level of
fixing of iodine to envisage a therapeutic application.

A first factor is the low level of expression
10 of the *nis* gene in tumor cells. For example, in the
abovementioned study, the results obtained *in vitro*
show that the concentration of iodine reached in
nonthyroid tumor cells remains approximately twice as
low as the iodine concentration accumulated in the
15 thyroid cells.

Furthermore, taking into account the large
disruptions which tumor cells exhibit at the membrane
level, it appears difficult to ensure the functional
integration of a transporter with an efficacy
20 comparable to that of nontumor thyroid cells.

Another limiting factor is the absence of
organification of iodine in nonthyroid cells; yet this
organification of iodine is a necessary component for
maintaining iodine in the cells. Thus, in the study
25 reported above, a very rapid efflux of the iodine
accumulated *in vitro* (between 30 and 60 min) is
observed for nonthyroid cells.

Finally, taking into account the heterogeneity of the tumor cells and of the large modifications of these cells at the membrane level, it appears difficult to be able to reach a homogeneous
5 distribution of the NIS transporter in the membranes of tumor cells.

Thus, no approach described now has yet made it possible to reach an accumulation of iodine in the nonthyroid tumor with a sufficient level of expression
10 to envisage the use of iodine-131 for the treatment of nonthyroid tumors.

The present invention presents an improved method of treating tumors combining gene therapy and radiotherapy with iodine-131.

15 The present invention describes in particular a method which makes it possible to increase the efficacy of the fixing of iodine at the level of nonthyroid tumors and which thus makes it possible to apply to the nonthyroid tumors the principles of
20 radiotherapy successfully developed for the treatment of thyroid cancers.

The present invention results from the demonstration that the transfer of the gene encoding the specific iodine transporter (Na^+/I^- Symporter) NIS
25 by means of a defective recombinant adenovirus makes it possible to reach a very high accumulation of iodine in nonthyroid tumor cells. In a specific embodiment, the supply of a defective adenovirus expressing the *nis*

gene makes it possible to accumulate iodine at concentrations about five times as high as those observed in thyroid cells. This surprising capacity of nonthyroid tumor cells to accumulate iodine-125 makes it possible to envisage for this type of tumors a novel therapeutic approach based on metabolic radiotherapy with iodine-131, which approach was up until now reserved for the treatment of certain thyroid tumors.

The major benefit of metabolic radiotherapy is to deliver large irradiation doses to tissues fixing the radioactive isotope, without significantly irradiating the surrounding tissues.

The discovery that it is effectively possible to substantially concentrate iodine in tumor cells which are normally incapable of accumulating this element makes it possible to envisage the application of this method in numerous indications for the treatment of tumors of nonthyroid origin. Two types of indications are more particularly envisaged: tumors which are hardly accessible to external radiotherapy because of their location; by way of example, there may be mentioned inoperable prostate cancers or intracerebral tumors; tumors which have already been irradiated and for which additional external radiotherapy is impossible because the maximum doses have already been administered: this relates to all cancers occurring or relapsing in irradiated regions. This method is also applicable to the treatment of

It is also possible to envisage combining metabolic radiotherapy and external radiotherapy as is carried out in the case of metastases of differentiated thyroid cancer. This combination makes it possible to increase the therapeutic efficacy of the radiotherapy without increasing toxicity. This combination appears particularly advantageous for tumors which are not very sensitive to radiotherapy. Moreover, it makes it possible to envisage the application of this technique to tumors which would not be accessible to metabolic radiotherapy alone, because of their excessively large size.

For the purposes of the present invention, the expression "derivative" of the specific iodine transporter (Na^+/I^- Symporter) NIS is understood to mean any analogue, fragment or mutated form which is derived from the NIS polypeptide and which retains a specific iodine transporting activity. Various derivatives may exist in the natural state. These derivatives may be allelic variations characterized by differences in the nucleotide sequence of the structural genes encoding

NIS or may result from differential splicing or post-translational modifications. These derivatives may be obtained by substitution, deletion, addition and/or modification of one or more amino acid residues. These
5 modifications may be carried out by any techniques known to persons skilled in the art. These derivatives are in particular molecules having a higher affinity for their substrates, sequences allowing improved expression *in vivo*, molecules exhibiting greater
10 resistance to proteases, molecules having greater biological efficacy or fewer side effects, or possibly novel biological properties. Other derivatives which may be used in the context of the invention are in particular molecules in which one or more residues have
15 been substituted, derivatives obtained by deletion of regions not or not greatly involved in the interaction with the binding sites considered or expressing undesirable activity, and derivatives comprising additional residues relative to the native sequence,
20 such as for example a secretory signal and/or a joining peptide.

The specific iodine transporter (Na^+/I^- Symporter) NIS or its derivative, which is produced in the context of the present invention, may be a cDNA, a
25 genomic DNA (gDNA), or a hybrid construct consisting, for example, of a cDNA into which one or more introns would be inserted. It may also include synthetic or semi-synthetic sequences. Advantageously, a cDNA or a

gDNA is used. In particular, the use of a gDNA may allow better expression in human cells.

According to a first embodiment, it is a cDNA sequence encoding the specific iodine transporter (Na⁺/I⁻ Symporter) NIS of murine origin. According to a preferred embodiment of the invention, it is a cDNA sequence encoding the specific iodine transporter (Na⁺/I⁻ Symporter) NIS of human origin.

The adenoviruses used in the context of the present invention are recombinant adenoviruses, that is to say which comprise a heterologous DNA sequence. Advantageously, they are defective recombinant adenoviruses, that is to say adenoviruses incapable of autonomous replication in the target cells.

For the construction of the adenoviruses according to the invention, various serotypes may be used. There are indeed numerous serotypes, whose structure and properties vary somewhat, but which exhibit a comparable genetic organization. More particularly, the recombinant adenoviruses may be of human or animal origin. As regards the adenoviruses of human origin, there may be preferably mentioned those classified in group C, in particular adenoviruses type 2 (Ad2), 5 (Ad5), 7 (Ad7) or 12 (Ad12). Among the various adenoviruses of animal origin, there may be preferably mentioned the adenoviruses of canine origin, in particular all the strains of CAV2 adenoviruses [manhattan or A26/61 strain (ATCC VR-800) for example].

Other adenoviruses of animal origin are cited in particular in application WO 94/26914.

The genome of the adenoviruses comprises in particular an inverted terminal repeat sequence (ITR) at each end, an encapsidation sequence (Psi), early genes and late genes. The main early genes are contained in the E1, E2, E3 and E4 regions. Among these, the genes contained in the E1 region in particular are necessary for viral propagation. The main late genes are contained in the L1 to L5 regions. The genome of the Ad5 adenovirus has been completely sequenced and is accessible on data base (see in particular Genbank M73260). Likewise, portions, or even the whole of other adenoviral genomes (Ad2, Ad7, Ad12, and the like) have also been sequenced.

As indicated above, the adenoviruses according to the invention are defective and therefore incapable of autonomously replicating in the target cell. To this effect, various constructs derived from adenoviruses have been prepared, incorporating various therapeutic genes. In each of these constructs, the adenovirus was modified so as to render it incapable of replicating in the infected cell. Thus, the constructs described in the prior art are adenoviruses from which there has been deleted the E1 region, which is essential for viral replication, into which heterologous DNA sequences are inserted (Levrero et al., Gene 101 (1991) 195; Gosh-Choudhury et al., Gene

50 (1986) 161). Moreover, to improve the properties of the vector, it has been proposed to create other deletions or modifications in the genome of the adenovirus. Thus, a heat-sensitive point mutation was introduced into the ts125 mutant, making it possible to inactivate the 72kDa DNA-binding protein (DBP) (Van der Vliet et al., J. Virol. 1975, 15(2) 348-354). Other vectors comprise a deletion of another region essential for viral replication and/or propagation, the E4 region. The E4 region is indeed involved in regulating the expression of the late genes, in the stability of the late nuclear RNAs, in the extinction of the expression of the proteins of the host cell and in the efficiency of the replication of the viral DNA.

15 Adenoviral vectors in which the E1 and E4 regions have been deleted therefore possess a transcriptional background noise and an expression of viral genes which are greatly reduced. Such vectors have been described for example in applications WO 94/28152, WO 95/02697, WO 96/22378. In addition, vectors carrying a modification in the IVa2 gene have also been described (WO 96/10088).

In a preferred embodiment of the invention, the recombinant adenovirus is a group C human adenovirus. More preferably, it is an Ad2 or Ad5 adenovirus.

Advantageously, the recombinant adenovirus used in the context of the invention comprises a

deletion in the E1 region of its genome. More particularly still, it comprises a deletion of the E1a and E1b regions. By way of example, there may be mentioned deletions affecting nucleotides 454-3328, 5 386-3446, 459-3510 or 357-4020 (with reference to the genome of Ad5).

According to another variant, the recombinant adenovirus used in the context of the invention is defective for all or part of the E1 and E3 regions at 10 least.

According to another variant, the recombinant adenovirus used in the context of the invention comprises, in addition to a deletion in the E1 region, a deletion affecting all or part of the E4 region of 15 its genome. More particularly, the deletion in the E4 region affects all the open phases. There may be mentioned, by way of precise example, the deletions 33466-35535 or 33093-35535 or only part of the E4 region (ORF6 or ORF3 for example), as described in 20 applications WO 95/02697 and WO 96/22378.

It may be, for example, so-called 3rd generation recombinant adenoviruses, that is to say which are defective for the E1 and E4 regions, as a whole or in part, and optionally for the E3 region. 25 Particular variants of the invention consist of the use of adenoviruses carrying deletions affecting all or part of the following functional regions:

- E1, E4 and E3,

The recombinant adenoviruses are produced in an encapsidation line, that is to say a line of cells capable of complementing in trans one or more of the functions deficient in the recombinant adenoviral genome. Among the encapsidation lines known to persons skilled in the art, there may be mentioned for example the 293 line into which part of the adenovirus genome has been integrated. More precisely, the 293 line is a human embryonic kidney cell line containing the left end (about 11-12%) of the genome of the serotype 5 adenovirus (Ad5), comprising the left ITR, the encapsidation region, the E1 region, including E1a and E1b, the region encoding the pIX protein and part of the region encoding the pIVa2 protein. This line is capable of transcomplementing recombinant adenoviruses defective for the E1 region, that is to say which lack

all or part of the E1 region, and of producing viral stocks having high titres. This line is also capable of producing, at permissive temperature (32°C) stocks of virus comprising, in addition, the heat-sensitive E2
5 mutation. Other cell lines capable of complementing the E1 region have been described, based in particular on human lung carcinoma cells A549 (WO 94/28152) or on human retinoblasts (Hum. Gen. Ther. (1996) 215). Moreover, lines capable of transcomplementing several
10 adenovirus functions have also been described. In particular, there may be mentioned lines complementing the E1 and E4 regions (Yeh et al., J. Virol. Vol. 70 (1996) pp. 559-565; Cancer Gen. Ther. 2 (1995) 322; Krougliak et al., Hum. Gen. Ther. 6 (1995) 1575) and
15 lines complementing the E1 and E2 regions (WO 94/28152, WO 95/02697, WO 95/27071) or lines derived therefrom which can be used for producing minimum adenoviruses, in particular because they express, in addition, a site-specific recombinase activity involved in the
20 construction of such viruses.

The recombinant adenoviruses may also be modified in the structure of the capsid in order to increase the efficiency of infection at the level of the tumor. For example, the capsid may contain a uPAR
25 ligand or an RGD motif which allows targeting of the adenovirus to the tumor cells, such vectors and targeting sequences have been described in particular in application WO 00/12738. The targeting sequences may

be inserted into the hexon protein or into the fibre protein. Preferably, the targeting sequences are inserted at the level of the deletion of the protein of the fibre or of the hexon. There are advantageously
5 deleted from the polypeptide sequence of the hexon 13 amino acids corresponding to positions 279 to 292 of the polypeptide sequence of the hexon of Ad 5. There are advantageously deleted from the polypeptide
10 positions 539 to 547 of the polypeptide sequence of the fibre (HI Loop) of Ad 5.

The recombinant adenoviruses are usually produced by introducing the viral DNA into the encapsidation line, followed by lysis of the cells
15 after about 2 or 3 days (the kinetics of the adenoviral cycle being 24 to 36 hours). For the implementation of the method, the viral DNA introduced may be the complete recombinant viral genome, optionally constructed in a bacterium (WO 96/25506) or in a yeast
20 (WO 95/03400), infected into the cells. It may also be a recombinant virus used to infect the encapsidation line. The viral DNA may also be introduced in the form of fragments each carrying part of the recombinant viral genome and a homologous region which makes it
25 possible, after introduction into the encapsidation cell, to reconstitute the recombinant viral genome by homologous recombination between the various fragments.

Sequences for regulating expression. The gene encoding the specific iodine transporter (Na^+/I^- Symporter, NIS) may be placed under the control of any sequence for regulating expression such as for example a promoter or a promoter/enhancer, which is functional and which allows expression in the host tumor cells.

The sequences for regulating expression may comprise, in addition to the promoter region, a region situated in 3' of the gene encoding the specific iodine transporter and which provides a signal for termination of transcription and a polyadenylation site. All these elements constitute an expression cassette.

The promoter may be constitutive or regulatable (inducible). It may be the actual promoter of the gene. It may also include sequences of a different origin (which are responsible for the expression of other proteins, or even a synthetic promoter). In particular, it may include promoter sequences of eukaryotic or viral genes. For example, it may include promoter sequences derived from the genome of the cell which it is desired to transfect. Likewise, it may include promoter sequences derived from the genome of a virus, including of the virus used. In this

In addition, these expression sequences may be modified by the addition of activation or regulatory sequences allowing tissue-specific or predominant expression in certain tissues (enolase promoter GFAP, and the like). It may indeed be particularly advantageous to use expression signals which are active specifically or predominantly in the tumor cells, so that the therapeutic gene is expressed or produces its effect only when the virus has effectively infected a tumor cell. The specific or predominant character of the expression means that the activity of the promoter is significantly much higher in the tumor cells.

Among the promoters which can be used in the context of the invention, there may be mentioned the ubiquitous promoters (HPRT, vimentin, α -actin, tubulin, and the like), the promoters of the intermediate
25 filaments (desmin, neurofilaments, keratin, GFAP), the promoters of genes of therapeutic interest (MDR, CFTR, factor VIII and the like), the tissue-specific promoters (promoters of the genes for desmin, myosins,

in the liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), the regulatory sequence of the alpha-fetoprotein gene which is active in the liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58), the regulatory sequence of the alpha 1-antitrypsin gene which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), the regulatory sequence of the β -globin gene which is active in myeloid cells (Mogam et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), the regulatory sequence of the gene for basic myelin which is active in the oligodendrocytes in the brain (Readhead et al., 1987, Cell 48:703-712), the regulatory sequence of the gene for myosin light chain 2 which is active in the skeletal muscle (Sani, 1985, Nature 314:283-286), and the regulatory sequence of the gene for the gonadotrophin-releasing hormone which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

20 In a specific embodiment of the invention, a defective recombinant adenovirus is used which comprises a gene encoding the specific iodine transporter (Na^+/I^- Symporter) NIS under the control of a viral promoter, preferably chosen from RSV-LTR or the
25 CMV early promoter.

It is also possible to combine the introduction of the NIS gene with the vector according to the invention with the introduction of a biological

system which makes it possible to increase the biological half-life of iodine-131. It is thus possible to simultaneously or successively deliver into the tumor cells the NIS gene and a gene or several genes encoding polypeptides involved in an iodine organification system. There may be mentioned, for example, genes encoding polypeptides involved in a peroxidase system such as the gene encoding glucose oxidase. There may also be mentioned the gene encoding thyroperoxidase, an enzyme in the thyroid cells involved in the iodine organification process (Nucleic Acids Res. 15:6735-6735 (1987): sequence GenBank g37251). The introduction of the gene encoding thyroperoxidase may also be combined with the introduction of nucleic sequences encoding all or part of thyroglobulin (parts of thyroglobulin rich in tyrosin residues).

It is also possible to envisage delivering into the tumor cells the NIS gene and a gene or several genes encoding polypeptides involved in an iodine organification system by means of a single vector expressing several transgenes or by coinfection of two vectors, an adenoviral vector expressing the NIS gene and another vector, the viral or plasmid vector, expressing one or more genes encoding polypeptides involved in an iodine organification system.

It is, in addition, possible to combine the introduction of the NIS gene with the vector according

to the invention with the administration of a system allowing a slowing down of the iodine efflux by a pharmacological agent (for example a lithium salt).

According to another variant, it is also possible to envisage combining the introduction of the NIS gene with other genes of therapeutic interest for the treatment of cancers. This may include a suicide gene such as the gene for the Herpes thymidine kinase or the gene for cytosine deaminase. It may include genes encoding proteins inducing apoptosis such as p53, Bax, BclX-s, Bad or any other antagonist of Bcl2 and BclX-1. This may include genes encoding variants of these proteins exhibiting improved properties such as a variant of p53 (CTS-1, WO 97/04092). This may also include genes encoding anti-angiogenic or angiostatic factors such as in particular the ligand for Tie-1 and Tie-2, angiostatin, endostatin, ATF factor, plasminogen derivatives, endothelin, thrombospondins 1 and 2, PF-4, interferon α or β , interleukin 12, TNF α , urokinase receptor, flt1, KDR, PAI1, PAI2, TIMP1, prolactin fragment. This may also include genes encoding proteins capable of inducing antitumor immunity or of stimulating immune response (IL2, GM-CSF, IL12, and the like). Among the genes encoding proteins of therapeutic interest in the treatment of cancers, it is also important to emphasize antibodies, variable fragments of single chain antibodies (ScFv) or any other antibody fragment possessing recognition capacities for use in

immunotherapy for the treatment of tumors: anti-RAS antibodies (WO 9429446).

Advantageously, this may include a gene whose expression causes radiosensitization of tumor cells
5 such as the p53 gene.

The administration of these genes or of the combination of two or more of these abovementioned genes of therapeutic interest may be carried out by introducing one or more of these genes into the
10 adenoviral vector comprising the gene encoding the NIS transporter or into a separate vector of viral or nonviral nature.

According to another variant, the vector according to the invention may be administered in
15 combination with an anticancer agent such as in particular taxol, taxoter and other taxoids [as described in particular in US 4,857,653; US 4,814,470; US 4,924,011; US 5,290,957; US 5,292,921; US 5,438,072; US 5,587,493; EP 0 253 738; and WO 91/17976, WO
20 93/00928, WO 93/00929 and WO 9601815], or other therapeutic anticancer agents such as cis-platin and derivatives of platinum, etoposide and etoposide phosphate, bleomycin, mitomycin C, CCNU, doxorubicin, daunorubicin, idarubicin, ifosfamide, and the like.

25 The invention also relates to a pharmaceutical composition comprising an adenoviral vector as described above and a physiologically acceptable vehicle. The pharmaceutical compositions of

the invention are preferably in an injectable form and may be formulated for intratumoral administration or for administration by the oral, parenteral, intranasal, intraarterial, intravenous or intratracheal route, and
5 the like.

Preferably, the pharmaceutical composition contains pharmaceutically acceptable vehicles for a formulation intended to be administered by the intratumoral route.

10 The compositions according to the invention may comprise variable doses of recombinant adenoviruses, which can be easily adjusted by persons skilled in the art according to the applications envisaged and various parameters, and in particular
15 according to the mode of administration used or alternatively the duration of the expression desired. In general, the recombinant viruses according to the invention are formulated and administered in the form of doses of between 10^4 and 10^{14} pfu, and preferably 10^6
20 to 10^{11} pfu. The term pfu ("plaque forming unit") corresponds to the infectivity of the virus, and is determined by infecting an appropriate cell culture, and measuring the number of infected cell plaques. The techniques for determining the pfu titre of a viral
25 solution are well documented in the literature.

In addition, the compositions according to the invention may also comprise a chemical or biochemical transfer agent. The term "chemical or

The term "effective quantity" designates a quantity sufficient to reduce by at least approximately 15%, preferably by at least 50%, and preferably still by at least 90% the volume of the tumors, and more preferably still a quantity sufficient to eliminate the tumors when the administration of the adenovirus comprising a nucleic acid encoding the iodine transporter (NIS) is combined with a metabolic radiotherapy treatment with iodine-135.

10 The invention relates to the treatment of tumors and more particularly the treatment of solid tumors. Among the solid tumors which may be treated by the subject of the invention, there may be mentioned in particular sarcomas and carcinomas, and by way of
15 nonlimiting example, fibrosarcomas, osteogenic sarcomas, angiosarcomas, endotheliosarcomas, lymphangiosarcomas, Ewing tumors, colon cancer, pancreatic cancer, ovarian cancer, prostate cancer, adenocarcinomas, carcinomas of the kidney, liver or
20 bile duct, Wilm's tumor, cervical cancer, testicular cancer, lung cancer, non-small-cell lung cancer, bladder cancer, epithelial carcinomas, gliomas, astrocytomas, melanomas, neuroblastomas and retinoblastomas.

25 The invention also relates to the prevention and/or treatment of proliferated disorders (such as metaplasias and displasias) of the epithelial tissues such as the epithelium of the cervix, of the oesophagus

and of the lungs. In this regard, the invention relates to the treatment of conditions known or suspected to precede a progression to a neoplasia or a cancer, in particular in states where the growth of non-neoplastic cells such as hyperplasia, metaplasia and more particularly dysplasia occurs (for a review of these abnormal growth conditions, see Robbins and Angell, 1976, *Basic Pathology*, 2nd Ed., W.B. Saunders Co., Philadelphia, pp. 68-79). Hyperplasia is a form of controlled cell proliferation involving an increase in the number of cells in an organ, without significant structural or functional alteration of this organ. For example, a hyperplasia of the endometrium may precede cancer of the endometrium. Metaplasia is a controlled form of cell growth in which a type of adult or completely differentiated cell becomes substituted for another type of cell. Metaplasia may occur in epithelial tissues or in conjunctive tissues. Dysplasia is often an early warning sign of cancer and is found mainly in the epithelium; it is the most frequent form of neoplastic cell growth, involving the loss of uniformity of the individual cells and the loss of the structural orientation of the cells. Dysplasia typically occurs when a chronic irritation or inflammation exists, and is often observed in the cervix, the respiratory tracts, the vocal cavity, and on the bladder wall. For a review, see Fishman et al.,

1985, *Medicine*, 2nd Ed., J.B. Lippincott Co.,
Philadelphia.

The present invention will be described in
5 greater detail with the aid of the following examples
which should be considered as illustrative and
nonlimiting.

LEGEND TO THE FIGURES

10

Figure 1: Diagram of the plasmid pAB1, of the
plasmid pXL3048 and of the plasmid pAB2. The plasmid
pXL3048 comprises the left end of the adenovirus type 5
genome (nucleotides 1-382), a polylinker comprising
15 three unique cloning sites and part of the pIX gene
(nucleotides 3446-4296). The plasmid pAB2 results from
the cloning of the SspI-EcoRV fragment of pAB1 into
pXL3048 previously linearized with EcoRV.

Figure 2: Production of the plasmid pXL3215
20 generated by double recombination from the plasmids
pAB2 and pXL3215 according to the method described by
Crouzet *et al.* (PNAS vol. 94, p1414, 1997). The plasmid
pXL3215 contains the adenovirus type 5 genome deleted
for the E1 and E3 region and contains the NIS
25 expression cassette.

Figure 3: Kinetics of accumulation of iodine-
125 by the FTRL-5 and SiHa cells infected with the Ad-
NIS vector (multiplicity of infection 10). The results

of the kinetics are expressed as number of counts per minute per 10^6 cells. The determination of the number of cells per well at the time of contact with iodine is the mean of two measurements.

5 Figure 4: Specific inhibition of the transport of iodine by NIS in the presence of perchlorate (NaClO_4) 30, 300 and 3000 μM . The contact time between the cells and iodine-125 is 15 minutes.

 Figure 5: Accumulation of iodine *in vivo* by
10 tumors infected with the Ad-NIS vector. The MCF-7 cells (human tumor cells of mammary cancer) were injected subcutaneously into nude mice (5×10^6 cells). After 15 days (start of appearance of the tumors), daily intraperitoneal injections of thyroxine
15 (2 $\mu\text{g}/\text{animal}/\text{day}$) were carried out for 15 days. The Ad-CMV-NIS vector was then injected into certain animals by the intratumoral route (2×10^9 pfu/tumor; size of the tumors 3-6 mm). Three days after the infection, 6 μCi of ^{125}I are injected into mice by the
20 intraperitoneal route. The countings were carried out over 10 seconds at regular time intervals by placing the probe over the thyroid, over the tumor, and immediately near the tumor. The results are expressed as number of counts detected (measurement over 10
25 seconds) as a function of time.

 Figure 6: Scintigraphy for a mouse whose tumor was infected with the Ad-NIS vector. The MCF-7 cells (human tumor cells, mammary cancer) were injected

subcutaneously into nude mice (5×10^6 cells). After 15 days (start of appearance of the tumors), daily intraperitoneal injections of thyroxine (2 μ g/animal/day) were carried out for 15 days. The Ad-
 5 NIS vector was then injected by the intratumor route (2×10^9 pfu/tumor; size of the tumors 3-6 mm). Three days post-infection, 50 μ Ci of 123 I are injected by the intraperitoneal route into the mice. The countings are carried out 1 hour after injection of iodine. The image
 10 is a ventral view of the animal.

MATERIALS AND METHODS

General molecular biology techniques

The methods conventionally used in molecular
 15 biology such as preparative extractions of plasmid DNA, centrifugation of plasmid DNA in cesium chloride gradient, agarose or acrylamide gel electrophoresis, purification of DNA fragments by electroelution, extractions of proteins with phenol or with phenol-
 20 chloroform, precipitation of DNA in saline medium with ethanol or isopropanol, transformation in *Escherichia coli*, and the like, are well known to persons skilled in the art and are abundantly described in the literature [Maniatis T. et al., "Molecular Cloning, a
 25 Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982; Ausubel F.M. et al. (eds), "Current Protocols in Molecular Biology", John Wiley & Sons, New York, 1987].

For the ligations, the DNA fragments may be separated according to their size by agarose or acrylamide gel electrophoresis, extracted with phenol or with a phenol/chloroform mixture, precipitated with
5 ethanol and then incubated in the presence of T4 phage DNA ligase (Biolabs) according to the supplier's recommendations.

The filling of the protruding 5' ends may be carried out with the Klenow fragment of DNA polymerase
10 I of *E. coli* (Biolabs) according to the supplier's specifications. The destruction of the protruding 3' ends is carried out in the presence of T4 phage DNA polymerase (Biolabs) used according to the manufacturer's recommendations. The destruction of the
15 protruding 5' ends is carried out by a controlled treatment with S1 nuclease.

Mutagenesis directed in vitro by synthetic oligodeoxynucleotides may be carried out according to the method developed by Taylor et al. [Nucleic Acids
20 Res. 13 (1985) 8749-8764] using the kit distributed by Amersham.

The enzymatic amplification of DNA fragments by the so-called PCR technique [Polymerase-catalyzed Chain Reaction, Saiki R.K. et al., Science 230 (1985)
25 1350-1354; Mullis K.B. and Faloona F.A., Meth. Enzym. 155 (1987) 335-350] may be carried out using a "DNA thermal cycler" (Perkin Elmer Cetus) according to the manufacturer's specifications.

5

Example 1 : Construction of a defective recombinant adenovirus expressing the gene encoding the specific iodine transporter (Na^+/I^- Symporter) NIS.

The fragment comprising nucleotides 74 to 2046 of the sequence of the rat *nis* gene (Dai et al., 1996, Nature 379: 458-460) was cloned in the form of an AatII-HindIII fragment into the PvuII-HindIII sites of the plasmid pCEP-4 (Invitrogen). The AatII site of the AatII-HindIII fragment was previously made blunt by treating with Mung Bean nuclease (Biolabs) before insertion into the plasmid pCEP-4. The resulting plasmid is called pAB1.

25 The plasmid pAB1 (Figure 1) comprises the *nis*
gene whose expression is placed under the control of
the cytomegalovirus CMV enhancer/promoter (nucleotides
-522 to +72) (Boshart et al. 1985, Cell, 41: 521 - 530)

